AD NUMBER

ADB274588

NEW LIMITATION CHANGE

TO
Approved for public release, distribution unlimited

FROM
Distribution authorized to U.S. Gov't. agencies only; Proprietary Information; May 2001. Other requests shall be referred to US Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, MD 21702-5012

AUTHORITY

USAMRMC ltr, 1 Apr 2003

THIS PAGE IS UNCLASSIFIED
Award Number: DAMD17-99-1-9014

TITLE: Identification of Cellular and Molecular Markers of Prostate Cancer Progression in Racial-Ethnic Minorities

PRINCIPAL INVESTIGATOR: Richard J. Cote, M.D.

CONTRACTING ORGANIZATION: University of Southern California
Los Angeles, California 90033

REPORT DATE: May 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, May 01). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-99-1-9014
Organization: University of Southern California

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

______________________________  
______________________________

Nina S. Nagel  
01/07/2002
<table>
<thead>
<tr>
<th>1. AGENCY USE ONLY (Leave blank)</th>
<th>2. REPORT DATE</th>
<th>3. REPORT TYPE AND DATES COVERED</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>May 2001</td>
<td>Annual (1 Nov 99 - 30 Apr 01)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. TITLE AND SUBTITLE</th>
<th>5. FUNDING NUMBERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identification of Cellular and Molecular Markers of Prostate Cancer Progression in Racial-Ethnic Minorities</td>
<td>DAMD17-99-1-9014</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. AUTHOR(S)</th>
<th>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard J. Cote, M.D.</td>
<td>University of Southern California</td>
</tr>
<tr>
<td></td>
<td>Los Angeles, California 90033</td>
</tr>
<tr>
<td></td>
<td>E-Mail: <a href="mailto:cote_r@mikey.hsc.usc.edu">cote_r@mikey.hsc.usc.edu</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>8. PERFORMING ORGANIZATION REPORT NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</th>
<th>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. Army Medical Research and Materiel Command</td>
<td></td>
</tr>
<tr>
<td>Fort Detrick, Maryland 21702-5012</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11. SUPPLEMENTARY NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12a. DISTRIBUTION / AVAILABILITY STATEMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distribution authorized to U.S. Government agencies only (proprietary information, May 01). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12b. DISTRIBUTION CODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>12a. DISTRIBUTION / AVAILABILITY STATEMENT</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>13. ABSTRACT (Maximum 200 Words)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Our specific aims are to examine men with prostate cancer from 4 different racial-ethnic groups to determine the prevalence of molecular and cellular changes that may play a role in prostate tumor progression, particularly invasion and metastasis. We are currently assessing tissue samples from patients with prostate cancer for markers involved in the following pathways: a) hormonal regulation and responsiveness, b) cell cycle regulation c) tumor angiogenesis and its regulators and d) invasion and metastasis. When our tissue analysis is completed we will determine the relationship between the changes in these key biological pathways and race/ethnicity, age and the intermediate markers of disease progression (i.e. tumor grade and stage). Finally, these molecular and cellular changes will be related to clinical outcome (i.e. survival and mortality) within and between racial/ethnic groups.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>14. SUBJECT TERMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>15. NUMBER OF PAGES</th>
<th>16. PRICE CODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>17. SECURITY CLASSIFICATION OF REPORT</th>
<th>18. SECURITY CLASSIFICATION OF THIS PAGE</th>
<th>19. SECURITY CLASSIFICATION OF ABSTRACT</th>
<th>20. LIMITATION OF ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unclassified</td>
<td>Unclassified</td>
<td>Unclassified</td>
<td>Unlimited</td>
</tr>
</tbody>
</table>
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

[Signature]
PI - Signature Date
# Table of Contents

Front Cover

Report Documentation Page 2

Foreword 3

Table of Contents 4

Introduction 5

Body 6-7

Key Research Accomplishments 7

Reportable Outcomes 7

Conclusions 7

References 8

Appendices 9-10
INTRODUCTION

Prostate cancer continues to be a major health risk for men, and in fact, is the most frequently diagnosed cancer in the United States. Prostate cancer is remarkable for the extraordinary variation in incidence, mortality and survival among different racial-ethnic populations of men. African-American men have the highest rates of prostate cancer in the world and have substantially shorter survival times, even when analyzed on a stage by stage basis. Conversely, Asian men from China, Japan and Korea have the lowest rates of prostate cancer and appear to have substantially better survival times. Whites and Latinos have an intermediate incidence of disease occurrence and intermediate long-term survival times.

Although the epidemiology and etiology of prostate cancer is largely unknown and it is known to be a highly heterogenous disease with an unpredictable course, the steps that lead to tumor progression (i.e. invasion and metastases) are becoming increasingly well characterized. Among these are the following:

- Loss of hormonal regulation that can also have important implications in the control of metastatic disease.
- Loss of cell cycle control: loss of tumor suppressor function (e.g. p53, Rb, PTEN) that can have multiple effects on regulation of cell growth, angiogenesis, and the ability of a tumor to enter the cell death (apoptotic) pathway. Similarly, inactivation of cdk-inhibitors (p27,p21,p16) is expected to result in increased proliferation rates of tumor cells (as detected by PCNA, Ki67 and Topoisomerase II expression).
- Loss of growth control: in the past few years, a number of groups have identified loss of function of the PTEN phosphatase as a common event, particularly in advanced prostate cancer. The primary consequence of loss of PTEN function is deregulation of the PI3-kinase Akt pathway, which is oncogenic in many tumor models. By measuring the status if this pathway at multiple levels, we will be defining the frequency of this change in multiple ethnic groups.
- The ability to form a new blood supply (angiogenesis) a factor vital for the transport of nutrients and removal of wastes from a tumor as well as providing a route for tumor metastasis. Loss of normal inhibitors of angiogenesis (thrombospondin-1) can lead to increased neovascularization (detected by microvascular density).
- Loss of normal cell matrix adhesion properties and cell-cell interactions (including contact inhibition), that allows tumor cells to grow past normal cell density and to break away from their primary site and form occult metastases, or overt metastases.

We are in the process of determining the relationship between changes in these key biological pathways and a) race/ethnicity, b) age, and c) intermediate markers of tumor progression (tumor stage and grade). We will eventually be in a position to relate these changes to the overall and disease-free rates, across racial-ethnic groups.
BODY

We are in the process of testing our hypothesis that the difference in tumor behavior among the different racial-ethnic groups as a molecular and cellular basis. We have been collecting specimens from the CSP Slide Retrieval Resource, a component of the Tissue Procurement Core Resource of the USC/Norris Comprehensive Cancer Center. This core resource handles all requests to hospitals and freestanding pathology laboratories for tumor tissue. In addition, we have been able to obtain tissue using the SEER registry in Los Angeles County, a highly multiethnic population. We have collected over 161 tumor samples from patients with prostate carcinoma. Initial delays in collecting these samples were encountered due to difficulty in procuring the tissues from the participating institutions. However, as stated we have over 161 samples and continue to collect samples. The registry maintains the main patient database and provides us with glass slides from patients with prostate cancer, stripped of patient names. During our analysis of the tissues, we are blinded to the clinical stage and grade of the tumor as well as to the patient's race. The Department of Preventative Medicine headed by our Co-investigator, Dr. Ronald Ross, maintains a complete database concerning the relevant clinical and demographic information regarding the patient as well as the links to the patient identification from all cohorts of patient samples being examined. We receive the specimens from the Department of Preventative Medicine, labeled with a pathology number and a study number. We enter these data into our laboratory database a give them laboratory numbers. The results are transmitted back to the Department of Preventative Medicine for statistical analysis. We assess all the tumor tissue obtained to ensure uniform pathologic tumor grading and to evaluate the suitability for its use in this project. These tumor samples are in the process of being analyzed for various factors that are thought to play a role in tumor progression. These factors include p27, bcl-2, E-cadherin, p53, Rb, CD34, p16, Ki67, PCNA, Topoisomerase-II and thrombospondin-1.

Since beginning this project new and exciting data regarding Cyclooxygenase-2 (COX-2), a carcinogen-activating (Phase 1) enzyme thought to exhibit an inhibitory effect on apoptosis, activity and tumor progression in cancer has been reported. Three recent, relatively small and non-population based studies of bladder cancer have demonstrated expression of COX-2. In the first study, COX-2 expression was detected in 25/29 (86%) invasive transitional cell carcinomas of the urinary bladder and in 6/8 (75%) cases carcinoma in situ. In the second study, 12/16 transitional cell carcinoma specimens were COX-2 positive compared with 2/8 'normal' adjacent tissues (p=0.03). Finally, Liebert et al showed that while low-stage bladder cancers were generally negative for COX-2 (4/14 Ta/T1/TIS expressed COX-2), most invasive tumors (10/12) expressed COX-2. In light of these exciting preliminary data regarding COX-2 and its potential role in the pathogenesis of cancer, we have added this to our list of markers to study in prostate cancer.

Due to the limited amounts of tumor we receive, not all markers can be performed on all tumors. Due to an unforeseen turnover in laboratory technical staff, there was a delay in the initial processing of these specimens. We now have 2 new full-time technicians who are now fully-trained to process these specimens. For these reasons we have been
granted a 1-year, no cost extension. We fully expect to have reached our objectives, with the exception of the long-term recurrence and survival outcomes by April 2002.

These studies are expected to provide information leading to better understanding of prostate cancer progression in men of different racial-ethnic groups. Preliminary results show differences p27 expression from tumor to tumor, however, the results are still blinded and no conclusions can yet be stated.

While our project will have emphasis on racial-ethnic variability, it will also address important issues concerning prostate cancer outcome for all men. Facts that predispose one group of men to have more aggressive tumor, may be predictive of behavior of prostate cancer in all men.

KEY RESEARCH ACCOMPLISHMENTS

- Accrual of more 161 prostate cancer samples
- Pathologic evaluation of tumor samples, including Gleason Grading, percent tumor and suitability of us in project
- Access database created for all tumor evaluation and marker results
- IHC on suitable tumor samples
- Assessment of markers by pathologist (DH)

REPORTABLE OUTCOMES

This project has served as the springboard for another project that has been funded by the DOD (DAMD-17-00-1-0102) led by Dr. Ronald Ross in which the SEER cohort of patients has been added as well as two new projects involving androgen receptor signaling in prostate cancer lead by Dr. G Coetzee and Dr. J Reinhardt. This new award has benefited this study by introducing a new cohort of patients without further costs to this project. Furthermore, this work has lead to the recent (June 1, 2001) submission of a SPORE Grant on Prostate cancer to the NIH.

A visiting research fellow Dr Weiguang Mo, a fully trained Pathologist from China will be joining the laboratory for one year to work on this project (see attached CV in appendix).

CONCLUSIONS

This study is a molecular epidemiologic study designed to elucidate the factors involved in disease progression. Our data will elucidate differences in prostate cancer risk and progression across multi-ethnic lines (African-American, Asian, Latino and white) including understudied populations of men. We have and are continuing to develop and apply novel biologic markers of prostate cancer progression.
REFERENCES

CURRICULUM VITAE

Name: Weiguang Mo
Address: Department of Histopathology
        St. George's Hospital Medical School
        Cranmer Terrace
        Tooting, London
        SW17 ORE, UK
Date of Birth: January 5, 1950
Place of Birth: Guangxi, China
Citizenship: Chinese
Sex: Male
Marital Status: Married

Appointments:
Vice Chairman, Department of Pathology, Guangxi Medical University, China
Professor, Guangxi Medical University, China

Professional Experience:
Sept 2, 2000 to Present - Visiting Academic, Department of Histopathology, St. George's Hospital Medical School, London, UK
July 1, 1996 to Sept 1, 2000 - Professor and Vice Chairman, Department of Pathology, Guangxi Medical University, China
July 1, 1990 to July 1, 1996 - Associate Professor, Department of Pathology, Guangxi Medical University, China
July 1, 1984 to July 1, 1990 - Assistant Professor, Department of Pathology, Guangxi Medical University, China
July 1, 1982 to July 1, 1984 - Resident, Residency in Pathology, Guangxi Medical University, China
July 1, 1976 to Sept 1, 1979 - Resident, Residency in Pathology, Guangxi Medical University, China

Education:
July 1, 1982 - Master Degree Medical Science in Zun-Yi Medical College, China
Sept 1, 1979 to July 1, 1982 - Graduate Student in Zun-Yi Medical College, China
Sept 1, 1973 to July 1, 1976 - Medical College Student, Guangxi Medical College, China

Selected Publications:
References:
Professor Qing-Yun Peng, Vice President, Guangxi Med. University, China
Dr. Yu-Rong Zou, Department of Anesthesiology, Guangxi Med. University, China
MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession document numbers be changed to "Approved for public release; distribution unlimited." Copies of these reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by e-mail at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:

Phyllis M. Rinehart
Deputy Chief of Staff for Information Management

Encl